{"id":15918,"date":"2020-04-24T06:48:16","date_gmt":"2020-04-24T11:48:16","guid":{"rendered":"http:\/\/www.paristn.net\/articles\/?p=15918"},"modified":"2020-04-23T23:54:11","modified_gmt":"2020-04-24T04:54:11","slug":"fda-coronavirus-covid-19-update-april-24th-2020","status":"publish","type":"post","link":"https:\/\/www.paristn.net\/articles\/2020\/04\/24\/fda-coronavirus-covid-19-update-april-24th-2020\/","title":{"rendered":"FDA Coronavirus (COVID-19) Update: April 24th, 2020"},"content":{"rendered":"

\"U.S.Silver Spring, MD<\/strong> – <\/span>The U.S. Food and Drug Administration (FDA) has announced the following actions taken in its ongoing response effort to the COVID-19 Coronavirus pandemic:<\/p>\n

Thursday, the FDA issued a guidance on non-invasive fetal and maternal monitoring devices<\/a> to help increase the availability and capability of these devices used to support patient monitoring during the COVID-19 Coronavirus pandemic.<\/p>\n

\"Coronavirus\"<\/a>

Coronavirus<\/p><\/div>\n

<\/p>\n

These prescription devices include fetal dopplers that lay users (such as patients or caregivers) could be instructed to use in a home setting under the direction of a health care provider as well as other fetal and maternal monitoring devices that could be used by a health care provider in a home setting.<\/p>\n

Increasing the availability of these devices may increase access to important prenatal data without the need for in-clinic visits and facilitate patient management by health care providers while reducing the need for in-office or in-hospital services during the COVID-19 Coronavirus public health emergency.<\/p>\n

Today, the FDA issued a guidance<\/a> to help increase availability and capability of imaging systems needed for diagnosis and treatment monitoring of lung disease in patients during the COVID-19 Coronavirus pandemic. These imaging products include medical x-ray, ultrasound, magnetic resonance imaging systems, and image analysis software that are used to diagnose and monitor medical conditions.<\/p>\n

Increasing the availability of mobile and portable imaging systems may increase options to image patients inside and outside of healthcare facilities, which could help to reduce the spread of COVID-19 Coronavirus.<\/p>\n

The FDA issued guidance<\/a> to communicate its temporary policy regarding certain requirements under the FDA Food Safety Modernization Act Accredited Third-Party Certification Program for foreign food entities and their products.<\/p>\n

The guidance addresses the current challenges with conducting onsite monitoring activities during the COVID-19 Coronavirus public health emergency by providing temporary flexibility so that recognized accreditation bodies (ABs) can maintain the accreditations of certification bodies (CBs), and so that already-issued certifications need not lapse, where certain safeguards are in place. See constituent update<\/a> for more.<\/p>\n

The FDA’s Best Practices for Retail Food Stores, Restaurants, and Food Pick-Up\/Delivery Services During the COVID-19 Pandemic<\/a>, is now available in Spanish<\/a>.<\/p>\n

Diagnostics update to date:<\/strong><\/p>\n